Business Wire

New landmark study reveals adults with diabetes at unnecessary risk of vision loss

14.11.2016 00:01 | Business Wire

Del

Despite vision loss being feared twice as much as other common complications of diabetes (including cardiovascular disease and stroke) a quarter of people with diabetes surveyed are not discussing eye complications with their health care professional, with many presenting when vision problems have already occured.1 These are some of the concerning insights into the current management of diabetic retinopathy (DR) and diabetic macular edema (DME) revealed by the DR Barometer Study, launched today via a unique collaboration of experts from the International Federation on Ageing (IFA), International Diabetes Federation (IDF), International Agency for the Prevention of Blindness (IAPB) and Bayer Pharma AG.

The true impact of DR and DME was clearly highlighted throughout the DR Barometer Study, which shows that 79% of people with DR find that their vision loss makes activities such as driving, going to work and completing basic household tasks difficult, and in some cases impossible.1 Furthermore, 20% of people with DR or DME also cite that changes in their vision leave them less able to manage their diabetes, an issue reflected in individuals’ perception of their overall health, with over half of respondents with DR rating their physical health as ‘poor to fair’.1

“Diabetic retinopathy is a leading cause of blindness in the working-age population of most developed countries and the sight loss caused by this condition can have a profound impact on both an individual’s quality of life and their ability to work,” said Peter Ackland, Chief Executive Officer, International Agency for the Prevention of Blindness (IAPB). “DR and DME can be successfully managed with the right screening and treatment, however many people with diabetes are being placed at unnecessary risk of vision loss due to barriers within the referral system and patient care pathway.”

The DR Barometer Study highlighted major capacity issues affecting access to eye examinations, which form a critical step in the detection and management of DR.1 This issue is clearly illustrated by the fact that both ophthalmologists and adults with diabetes who participated in the study reported ‘long waiting times to schedule an appointment’ as a major barrier to optimising eye health.1 One in three people with diabetes surveyed also confirm that even when they can book an appointment, the cost of the examination itself can be prohibitive, and 24% of patients said that waiting times at the clinic was a further issue.1

As well as exposing inadequacies within health care systems, the DR Barometer Study uncovers a worrying lack of guidelines for health care professionals.1 It reveals that half of all providers surveyed do not have written protocols for the detection and management of diabetes-related vision issues.1

The combined issues around capacity and cost for delivering screening, along with a lack of clarity around guidelines delivers a ‘perfect storm’ for this vulnerable population, both now and in the future; placing people with diabetes at risk of delays in diagnosis and treatment for diabetic eye disease. Close to two-thirds of ophthalmologists surveyed believe that late diagnosis is the greatest barrier to improving outcomes, with over half revealing that people with diabetes present when vision problems have already occurred and in many cases when it is too late for treatment.1

“We are currently experiencing one of the most important demographic upheavals of our time in terms of global population ageing, and the impact of non-communicable diseases such as diabetes is rising at a rapid rate.” said Dr Jane Barratt, Secretary General, International Federation on Ageing. “The DR Barometer Study exposes numerous barriers to timely screening, diagnosis and treatment for many people with diabetes – barriers which must be addressed head-on if we are to more effectively manage the consequences of these diseases as the at-risk group increases. A patient’s age, where they live or how much they earn should not be the defining factors in determining the management and treatment of their diabetes or any associated complications, such as diabetic eye disease.”

Along with their detailed research findings, the IFA, IAPB and IDF have also harnessed the DR Barometer Study to deliver a number of key evidence-based recommendations to address the knowledge gaps and inequalities in services for people with diabetes.

One crucial element of good patient outcomes is regular, affordable and accessible eye examinations for people with diabetes, along with affordable treatment delivered within a co-ordinated system, to ensure those at risk of vision loss are effectively monitored and managed. The experts behind the DR Barometer Study are also calling for significantly increased education - both for people with diabetes and health care professionals - regarding the prevention, detection and treatment of DR and DME. Equally important is the provision of tools for people with diabetes in all countries to be able to effectively manage their diabetes and prevent vision loss from occurring in the first place.

“The theme of this year’s World Diabetes Day is ‘Eyes on Diabetes’, which reflects how critical we believe the role of eye health to be within diabetes management,” said Dr David Cavan, MD, Director of Policy & Programmes, International Diabetes Federation. “The DR Barometer Study offers a number of steps that need to be taken now to prevent further vision loss from diabetes and we urge governments around the world to seriously consider how current approaches to diabetic eye disease can be improved.”

For further information and to download the full results of the DR Barometer, please visit www.drbarometer.com

Contact information

GCI Health
Charlotte Collins
Charlotte.collins@gcihealth.com
(0) 207 072 4214

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30Pressemelding

The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat

Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22Pressemelding

Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve

Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04Pressemelding

Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We

Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57Pressemelding

Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio

Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08Pressemelding

On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00Pressemelding

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom